Benzinga · Feb 23, 2026
AMEX · IGC
IGC Pharma, Inc.
Healthcare · Biotechnology
$0.27
Up+$0.01 (+1.91%)
Updated Sep 17, 2026, 11:47 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 27.44M
- P/E ratio
- -4.53
- Dividend yield
- 0.00%
- 52-week range
- $0.24 – $0.36
- Volume
- 473.63K
- Avg. volume
- 684.65K
Price performance
IGC price history
1M range · 20 trading sessions · Daily adjusted prices
IGC closed at $0.27 after 20 trading sessions, down 4.66% for the selected period.
- Last close
- $0.27
- Period change
- -4.66%
- Period low
- $0.27
- Period high
- $0.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.2734 | $0.2801 | $0.2664 | $0.272 | 473.63K |
| Sep 15, 2026 | $0.27 | $0.2785 | $0.265 | $0.2669 | 502.18K |
| Sep 14, 2026 | $0.2796 | $0.2848 | $0.27 | $0.2755 | 820.62K |
| Sep 11, 2026 | $0.2856 | $0.2905 | $0.2771 | $0.2786 | 415.68K |
| Sep 10, 2026 | $0.289 | $0.2905 | $0.281 | $0.283 | 623.94K |
| Sep 9, 2026 | $0.295 | $0.296 | $0.281 | $0.2815 | 347.77K |
| Sep 8, 2026 | $0.301 | $0.3027 | $0.2875 | $0.2899 | 572.3K |
| Sep 4, 2026 | $0.2974 | $0.30 | $0.2959 | $0.298 | 378.03K |
| Sep 3, 2026 | $0.297 | $0.3038 | $0.295 | $0.2985 | 349.31K |
| Sep 2, 2026 | $0.30 | $0.3042 | $0.295 | $0.2959 | 458.2K |
| Sep 1, 2026 | $0.30 | $0.306 | $0.2956 | $0.2967 | 775.86K |
| Aug 31, 2026 | $0.3067 | $0.3191 | $0.2941 | $0.2992 | 619.13K |
| Aug 28, 2026 | $0.328 | $0.335 | $0.3061 | $0.31 | 926.07K |
| Aug 27, 2026 | $0.311 | $0.341 | $0.311 | $0.3339 | 3.6M |
| Aug 26, 2026 | $0.31 | $0.31 | $0.3005 | $0.3077 | 454.2K |
| Aug 25, 2026 | $0.301 | $0.3078 | $0.30 | $0.3046 | 387.27K |
| Aug 24, 2026 | $0.31 | $0.31 | $0.30 | $0.3006 | 916.49K |
| Aug 21, 2026 | $0.2875 | $0.31 | $0.2787 | $0.308 | 1.87M |
| Aug 20, 2026 | $0.285 | $0.2852 | $0.2745 | $0.2772 | 603.64K |
| Aug 19, 2026 | $0.2844 | $0.2875 | $0.2801 | $0.2853 | 1.08M |
Latest IGC news
The latest Smart Investors Daily articles mentioning IGC.
Stock researchCompany · Overview
IGC research
Overview
Company profile and research snapshot.
Company profile
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| Apr 8, 2026 | Ascendiant Capital | Buy | — |
| Feb 23, 2026 | Ascendiant Capital | Buy | — |
| Dec 9, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 23, 2026
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $4.75 to $5.
Yahoo · Feb 12, 2026
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital ...
Yahoo · Feb 10, 2026
IGC Pharma Announces Equity Research Update by Alliance Global Partners
POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company. The ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
